Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA)
Hecht, JR; Lonardi, S; Bendell, JC; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Lin, Y; Rao, S; Ryoo, BY J CLIN ONCOL. 2020; 38(4):
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Ben Tran; Horvath, L; Rettig, M; Fizazi, K; Lolkema, MP; Dorff, TB; Greil, R; Machiels, JPH; Autio, KA; Rottey, S; Adra, N; Garje, R; Roncolato, F; Tagawa, ST; Shariat, SF; Salvati, M; Poon, S; Kouros-Mehr, H J CLIN ONCOL. 2020; 38(15):
Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score = 20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
Burtness, B; Rischin, D; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BG; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Ge, J; Swaby, R; Gumuscu, B; Harrington, K CANCER RES. 2020; 80(16):
Circulating tumor DNA-based decision for adjuvant treatment in colon cancer stage II evaluation: (CIRCULATE-trial) AIO-KRK-0217
Folprecht, G; Reinacher-Schick, A; Tannapfel, A; Weitz, J; Kossler, T; Weiss, L; Aust, DE; von Bubnoff, N; Kramer, M; Thiede, C J CLIN ONCOL. 2020; 38(4):
Emergency Extraction of a Draining Thrombus with ongoing Resuscitation
Parsch, W; Erdin, P; Welker, J; Geise, A; Ficker, JH PNEUMOLOGIE. 2020; 74: S33-S34.
COVID-19 treatment by anti-coagulation: anti-thrombotic and anti-inflammatory?
Paar, V; Wernly, B; Zhou, Z; Motloch, LJ; Hoppe, UC; Egle, A; Lichtenauer, M WIEN KLIN WOCHENSCHR. 2020; 132: S217-S217.
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Gianni, L; Huang, CS; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Bianchini, G; Russo, S; Ciruelos, E; Greil, R; Semiglazov, V; Colleoni, M; Kelly, C; Mariani, G; Del Mastro, L; Maffeis, I; Valagussa, P; Viale, G CANCER RES. 2020; 80(4):
REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC)
Singer, CF; Egle, D; Greil, R; Ohler, L; Petru, E; Suppan, C; Marhold, M; Pfeiler, G; Brunner, C; Tinchon, C; Halper, S; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Hennebelle, M; Mraz, B; Bartsch, R ANN ONCOL. 2020; 31: S77-S78.
Prognosis of triple negative metastatic breast cancer (MBC): Results from the AGMT_MBC-Registry
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R CANCER RES. 2020; 80(4):
Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
Murthy, R; Loi, S; Okines, A; Paplomata, E; Hamilton, E; Hurvitz, S; Lin, N; Borges, V; Abramson, VG; Anders, C; Bedard, PL; Oliveira, M; Jakobsen, E; Bachelot, T; Shachar, SS; Mueller, V; Braga, S; Duhoux, FP; Greil, R; Cameron, D; Carey, L; Curigliano, G; Gelmon, K; Hortobagyi, G; Krop, I; Loibl, S; Pegram, M; Slamon, D; Palanca-Wessels, MC; Walker, L; Feng, WT; Winer, E CANCER RES. 2020; 80(4):
